Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Cognitive Therapy for Treating Depression and Preventing Relapse
This study is currently recruiting participants.
Verified by National Institute of Mental Health (NIMH), February 2008
Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00183664
  Purpose

This study will compare the effectiveness of cognitive therapy versus antidepressant medication in treating depression and preventing relapse in individuals with recurrent depression.


Condition Intervention Phase
Depression
Drug: Fluoxetine
Behavioral: Cognitive therapy (CT)
Drug: Placebo
Phase IV

MedlinePlus related topics: Depression
Drug Information available for: Fluoxetine Fluoxetine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Prophylactic Cognitive Therapy for Depression

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:
  • Depressive relapse [ Time Frame: Measured at Month 9 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Psychosocial functioning [ Time Frame: Measured at Month 9 ] [ Designated as safety issue: No ]

Estimated Enrollment: 900
Study Start Date: December 1999
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Participants will receive continuation phase cognitive therapy for a total of 11 months of treatment
Behavioral: Cognitive therapy (CT)
All participants will receive 16 to 20 individual sessions of CT for 3 months. Participants assigned to continuation phase will receive additional sessions every other week for 8 weeks and then monthly for 6 months.
2: Active Comparator
Participants will receive 3 months of cognitive therapy and then 8 months of treatment with the antidepressant fluoxetine hydrochloride
Drug: Fluoxetine
Fluoxetine 10 to 40 mg/day for 8 months
Behavioral: Cognitive therapy (CT)
All participants will receive 16 to 20 individual sessions of CT for 3 months. Participants assigned to continuation phase will receive additional sessions every other week for 8 weeks and then monthly for 6 months.
3: Placebo Comparator
Participants will receive 3 months of cognitive therapy and then 8 months of treatment with placebo capsules
Behavioral: Cognitive therapy (CT)
All participants will receive 16 to 20 individual sessions of CT for 3 months. Participants assigned to continuation phase will receive additional sessions every other week for 8 weeks and then monthly for 6 months.
Drug: Placebo
Placebo daily for 8 months

Detailed Description:

Cognitive therapy (CT) is a form of therapy that focuses on changing negative thinking patterns and developing coping skills to deal with psychological problems. It encourages individuals to think, feel, and behave in a more positive manner. Previous research has shown that CT is effective for treating a number of psychological symptoms, including anxiety, anger, and loneliness. Many studies show that CT is, in fact, more effective than antidepressant medications for treating various psychological disorders. The "self-help" mentality and coping skills that are developed during CT tend to decrease the likelihood of depression relapse. While antidepressants often cause many unpleasant side effects such as dizziness, nausea, and increased heart rate, there are no known negative side effects associated with CT. The purpose of this study is to evaluate the effectiveness of CT versus antidepressant medication for treating depression and preventing relapse in individuals with recurrent depression.

This 36-month study will consist of three phases. During Months 1 through 3, participants will receive between 16 and 20 CT sessions. Participants will then be randomly assigned to receive additional CT sessions, antidepressant medication, or placebo for 8 months. Upon completing treatment, follow-up visits will occur once every 4 months for a total of 24 months. Outcome measurements will include standardized psychological tests and questionnaires to assess the participant's level of depression. All measurements will be assessed at Week 1, Week 12, and Months 8, 12, 16, 20, and 24.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Recurrent unipolar major depressive disorder
  • At least two episodes of major depression
  • At least one period of recovery during a depressive episode or a history of dysthymia (a mood disorder characterized by depression) prior to the onset of current or past depressive episodes
  • Able to speak and read English

Exclusion Criteria:

  • Active alcohol or other substance dependence within 6 months prior to study entry
  • Currently at risk for suicide
  • Current mood disorders due to a medical condition or substance abuse
  • Bipolar, schizoaffective, obsessive compulsive, or eating disorders
  • Schizophrenia
  • Unable to stop mood-altering medications
  • Current use of a medication that might cause depression
  • Diagnosis of a medical disorder that may cause depression (e.g., diabetes, head injury, stroke, cancer, multiple sclerosis)
  • Previous failure to experience a reduction in depressive symptoms after 6 weeks of 40 mg of Prozac
  • Pregnant or planning to become pregnant in the next 11-12 months
  • Unable to attend clinic twice weekly during business hours
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00183664

Contacts
Contact: Marna S. Barnett, PhD 215-746-6680 msb@mail.med.upenn.edu
Contact: Teresa Hinton 215-746-6680 hintont@mail.med.upenn.edu

Locations
United States, Pennsylvania
University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Judith A. Callan, RN, MSN     412-246-5734     callanja@upmc.edu    
Contact: Lisa M. Stupar     412-246-5757     stuparlm@upmc.edu    
Principal Investigator: Michael E. Thase, MD            
Sub-Investigator: Edward S. Friedman, MD            
Sponsors and Collaborators
Investigators
Principal Investigator: Michael E. Thase, MD The University of Pittsburgh School of Medicine
  More Information

Publications:
Responsible Party: University of Pennsylvania School of Medicine ( Michael E. Thase )
Study ID Numbers: R01 MH58356, DSIR 83-ATP
Study First Received: September 13, 2005
Last Updated: February 12, 2008
ClinicalTrials.gov Identifier: NCT00183664  
Health Authority: United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):
Depression
Cognitive Therapy
Relapse Prevention

Study placed in the following topic categories:
Fluoxetine
Depression
Mental Disorders
Mood Disorders
Depressive Disorder
Serotonin
Behavioral Symptoms

Additional relevant MeSH terms:
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs
Psychotropic Drugs
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Serotonin Uptake Inhibitors
Antidepressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 30, 2009